Physician profile
Greyson C Thomas
NPI 1467682104
$7,248.64
in general payments reported to CMS, 2019-2025
22 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,493 · 2020: $1,551 · 2021: $1,638 · 2022: $977 · 2023: $1,002 · 2024: $390 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,589.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,695.92 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $964.36 | 2019-2024 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $813.48 | 2019-2023 | Jardiance, Stiolto Respimat |
| Novo Nordisk INC | $748.37 | 2019-2023 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $561.66 | 2019-2023 | |
| Lilly USA, LLC | $359.59 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Pfizer INC. | $345.47 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $338.38 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $263.06 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $235.02 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $230.51 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $155.59 | 2021-2023 | |
| Mylan Specialty L.P. | $145.61 | 2019-2022 | |
| Amarin Pharma, INC. | $121.83 | 2019-2022 | |
| Abbvie INC. | $72.59 | 2023 | Qulipta, Ubrelvy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $50.35 | 2019-2021 | |
| Abbott Laboratories | $43.81 | 2022-2023 | Proclaim |
| Esperion Therapeutics, INC. | $36.09 | 2020-2021 | |
| Circassia INC. | $23.61 | 2019 | |
| Dexcom, INC. | $15.82 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.62 | 2019 | |
| Amgen INC. | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greyson Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.